EGFR (D770_N771insNPG/T790M)
Sign in to save this workspaceEGFR · Variant type: compound · HGVS: p.D770_N771insNPG;p.T790M
Components
p.D770_N771insNPGp.T790M
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Osimertinib | 99.8% | 0.2% | 97.24 |
| 2 | Brigatinib | 99.1% | 0.9% | 82.96 |
| 3 | Canertinib | 98.4% | 1.6% | 96.49 |
| 4 | Mobocertinib | 98.3% | 1.6% | 97.22 |
| 5 | Dacomitinib | 98.1% | 1.9% | 97.99 |
| 6 | Lazertinib | 95.6% | 4.4% | 97.47 |
| 7 | Fostamatinib | 93.3% | 6.7% | 96.74 |
| 8 | Pacritinib | 88.4% | 11.6% | 88.64 |
| 9 | Gilteritinib | 81.4% | 18.6% | 88.97 |
| 10 | Pralsetinib | 69.8% | 30.2% | 93.43 |
| 11 | Neratinib | 65.0% | 35.0% | 93.18 |
| 12 | Capmatinib | 63.0% | 37.0% | 99.75 |
| 13 | Erlotinib | 49.6% | 50.4% | 99.75 |
| 14 | Lorlatinib | 43.9% | 56.1% | 97.24 |
| 15 | Entrectinib | 40.6% | 59.4% | 93.69 |
| 16 | Alpelisib | 36.0% | 64.0% | 97.22 |
| 17 | Ibrutinib | 31.2% | 68.8% | 94.74 |
| 18 | Defactinib | 24.0% | 76.0% | 92.68 |
| 19 | Vandetanib | 23.9% | 76.1% | 95.74 |
| 20 | Alectinib | 22.6% | 77.4% | 95.49 |
| 21 | Fedratinib | 19.6% | 80.4% | 96.21 |
| 22 | Pemigatinib | 17.5% | 82.5% | 98.23 |
| 23 | Abemaciclib | 17.1% | 82.9% | 91.48 |
| 24 | Pazopanib | 14.7% | 85.3% | 97.49 |
| 25 | Quizartinib | 14.3% | 85.7% | 99.50 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Osimertinib | 99.8% | 99.1% | +0.7% |
| Brigatinib | 99.1% | 98.5% | +0.6% |
| Canertinib | 98.4% | 98.4% | -0.1% |
| Mobocertinib | 98.3% | 100.0% | -1.7% |
| Dacomitinib | 98.1% | 99.8% | -1.7% |
| Lazertinib | 95.6% | 100.0% | -4.4% |
| Fostamatinib | 93.3% | 97.8% | -4.4% |
| Pacritinib | 88.4% | — | — |
| Gilteritinib | 81.4% | 91.0% | -9.6% |
| Pralsetinib | 69.8% | 99.1% | -29.4% |
| Neratinib | 65.0% | 100.0% | -35.0% |
| Capmatinib | 63.0% | — | — |
| Erlotinib | 49.6% | 99.4% | -49.8% |
| Lorlatinib | 43.9% | — | — |
| Entrectinib | 40.6% | — | — |
| Alpelisib | 36.0% | — | — |
| Ibrutinib | 31.2% | 99.3% | -68.1% |
| Defactinib | 24.0% | 94.6% | -70.6% |
| Vandetanib | 23.9% | 99.3% | -75.4% |
| Alectinib | 22.6% | — | — |
| Fedratinib | 19.6% | — | — |
| Pemigatinib | 17.5% | — | — |
| Abemaciclib | 17.1% | — | — |
| Pazopanib | 14.7% | — | — |
| Quizartinib | 14.3% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 16.6ms